Instil Bio (TIL) Total Non-Current Liabilities (2020 - 2026)
Instil Bio (TIL) posted quarterly Total Non-Current Liabilities of $89.7 million for Q1 2026, down 2.95% year-over-year from $92.5 million in Q1 2025, and little changed quarter-over-quarter from $89.6 million in Q4 2025.
Instil Bio (TIL) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Instil Bio's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $89.7 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 2.95% year-over-year to $89.7 million; the TTM figure through Mar 2026 stood at $89.7 million (down 2.95% YoY), while the FY2025 annual figure was $89.6 million, down 4.68% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $89.7 million, roughly flat from $89.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $121.8 million in Q3 2022, with the low at $56.4 million in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $95.5 million (2024), against an average of $97.7 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities jumped 246.96% in 2022, then slipped 19.67% in 2023.
- Instil Bio's Total Non-Current Liabilities stood at $118.2 million in 2022, then retreated by 19.67% to $94.9 million in 2023, then dropped by 0.94% to $94.0 million in 2024, then dropped by 4.68% to $89.6 million in 2025, then grew by 0.08% to $89.7 million in 2026.
- Business Quant data shows TIL's Total Non-Current Liabilities at $89.7 million in Q1 2026, $89.6 million in Q4 2025, and $90.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 9.32 Bn |
| 10 | Instil Bio | 51.14 Mn | 51.14 Mn | - | 90.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.33 Mn |
| Mar 31, 2026 | 89.72 Mn |
| Dec 31, 2025 | 89.65 Mn |
| Sep 30, 2025 | 90.40 Mn |
| Jun 30, 2025 | 99.23 Mn |
| Mar 31, 2025 | 92.45 Mn |
| Dec 31, 2024 | 94.05 Mn |
| Sep 30, 2024 | 93.87 Mn |
| Jun 30, 2024 | 99.29 Mn |
| Mar 31, 2024 | 95.52 Mn |
| Dec 31, 2023 | 94.94 Mn |
| Sep 30, 2023 | 106.13 Mn |
| Jun 30, 2023 | 103.75 Mn |
| Mar 31, 2023 | 115.82 Mn |
| Dec 31, 2022 | 118.19 Mn |
| Sep 30, 2022 | 121.78 Mn |
| Jun 30, 2022 | 99.80 Mn |
| Mar 31, 2022 | 56.36 Mn |
| Dec 31, 2021 | 54.76 Mn |
| Sep 30, 2021 | 35.10 Mn |